Mounjaro®
Starting from £179.99/mo
Start journey Learn moreAfter a first semaglutide injection, most people notice changes within days — though rarely the ones they expect. The first week is about your body adjusting to the medicine, not about seeing a number drop on the scales. Some people feel less hungry almost immediately; others notice mild nausea before anything else. Both are normal. Semaglutide is a prescription-only medicine, and what you experience in week one depends on your starting dose, your individual response, and how well you support the medicine with food and hydration choices. A prescriber assesses your suitability before treatment begins and guides any changes along the way.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Yes, just not always what people are watching for. Semaglutide works by activating GLP-1 receptors in the brain and gut, slowing gastric emptying and signalling fullness. Those mechanisms can kick in quickly. Many people report eating noticeably less at their first or second meal after the injection, finishing portions they would previously have cleared without thinking. That early appetite shift is real, and it matters, it is what drives weight loss over time.
What you are unlikely to see after seven days is a dramatic fall on the scales. The opening dose (0.25 mg) is set intentionally low. Its purpose is to reduce the risk of nausea and vomiting as your body adapts, not to produce the weight-loss effect that comes at higher maintenance doses. The longer arc of semaglutide results shows that the medicine's effects compound through the titration schedule, which typically runs over several months.
A practical check you can do right now: jot down roughly how hungry you felt before your injection, then check in again 48–72 hours after. Many people find the contrast is sharper than they expected, even if the scales have not moved yet.
Nausea is the most commonly reported side effect in week one, and it catches people off guard because they were expecting to feel better, not worse. It happens because slowing gastric emptying (the same mechanism that reduces appetite) also means food sits in the stomach longer than your body is used to. For most people, the nausea is mild to moderate and settles within one to two weeks as the body adjusts.
Other GI effects in the early days can include constipation, loose stools, burping, or a general feeling of stomach fullness. Headache and mild fatigue are also reported. None of these are signs the medicine is not working, they are signs it is working, and that your system is responding. The timeline for Wegovy to work covers this adjustment period in more detail, including what to expect as doses increase.
Eating smaller portions, choosing lower-fat foods, and staying well hydrated can meaningfully reduce nausea in the first weeks. If symptoms are severe or persistent, contact your prescriber, do not simply stop the medicine.
The STEP 1 trial, published in the New England Journal of Medicine, followed adults using semaglutide 2.4 mg alongside lifestyle changes over 68 weeks. The average weight reduction reached around 15% of body weight. That figure reflects 68 weeks of treatment at the full maintenance dose, not week one at 0.25 mg.
Week one sits right at the start of a long curve. The titration from 0.25 mg through 0.5 mg, 1.0 mg, 1.7 mg and up to 2.4 mg happens gradually, typically over several months, guided by a prescriber. The appetite suppression and weight-loss effects strengthen as the dose increases. People often notice the clearest difference in weeks four to eight, you can read about what changes around that point on our semaglutide four-week results page.
The NHS semaglutide medicines page also sets out what to expect, including side effects and storage guidance, and is worth reading alongside your Patient Information Leaflet.
Partly, but not in the way most people assume. Feeling nauseous in week one does not mean the medicine will work better for you. Feeling no side effects does not mean it will not work. Both are poor predictors of long-term outcome. What matters more is consistency, taking each weekly dose at a roughly similar point in the week, following your prescriber's titration schedule, and pairing treatment with the kind of sustainable lifestyle changes that the clinical evidence shows make a real difference alongside GLP-1 medicines.
Some people do see small scale changes in week one (often related to reduced food intake and some fluid shifts) but these vary widely and should not be used to judge whether treatment is working. The week-by-week semaglutide results guide maps out what each phase of treatment typically brings, which is a more useful lens than a single early reading.
Semaglutide (Wegovy) is a prescription-only medicine. If you are considering treatment, or want to understand whether it could be right for you, our Wegovy overview covers eligibility, the titration process, and how private treatment works. For those thinking about the cost side, our Wegovy cost page explains what a legitimate private prescription includes. When you are ready to speak to a prescriber, start a free consultation with our team, a real clinician reviews your information the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.